Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation